Does the media prefer AMZN or VRTX?

In the previous week, Amazon.com had 226 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 277 mentions for Amazon.com and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Amazon.com's score of 0.94 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amazon.com 179 Very Positive mention(s) 45 Positive mention(s) 26 Neutral mention(s) 21 Negative mention(s) 4 Very Negative mention(s) Positive Vertex Pharmaceuticals 44 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or VRTX?

In the previous week, Vertex Pharmaceuticals had 41 more articles in the media than Axsome Therapeutics. MarketBeat recorded 51 mentions for Vertex Pharmaceuticals and 10 mentions for Axsome Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Axsome Therapeutics' score of 1.17 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 44 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or VRTX?

In the previous week, Vertex Pharmaceuticals had 48 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 51 mentions for Vertex Pharmaceuticals and 3 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat CRISPR Therapeutics' score of 0.66 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 44 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GOOG or VRTX?

In the previous week, Alphabet had 157 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 208 mentions for Alphabet and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Alphabet's score of 0.76 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alphabet 112 Very Positive mention(s) 35 Positive mention(s) 40 Neutral mention(s) 17 Negative mention(s) 3 Very Negative mention(s) Positive Vertex Pharmaceuticals 44 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRTX or ISRG?

In the previous week, Vertex Pharmaceuticals had 30 more articles in the media than Intuitive Surgical. MarketBeat recorded 51 mentions for Vertex Pharmaceuticals and 21 mentions for Intuitive Surgical. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Intuitive Surgical's score of 0.72 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 44 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Intuitive Surgical 11 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Vertex Pharmaceuticals (VRTX) Competitors

$547.29 -4.77 (-0.86%)

As of 10:21 AM Eastern

Compare

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

Should you buy Vertex Pharmaceuticals stock or one of its competitors? Vertex Pharmaceuticals's main competitors and comparable companies include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Alphabet (GOOG), and Intuitive Surgical (ISRG). Companies are selected based on similarities in market, industry, and size.

How does Vertex Pharmaceuticals compare to Amazon.com?

Amazon.com (NASDAQ:AMZN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Amazon.com has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Amazon.com currently has a consensus target price of $322.39, indicating a potential upside of 23.49%. Vertex Pharmaceuticals has a consensus target price of $563.50, indicating a potential upside of 2.96%. Given Amazon.com's stronger consensus rating and higher probable upside, analysts clearly believe Amazon.com is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amazon.com	0 Sell rating(s)	2 Hold rating(s)	56 Buy rating(s)	1 Strong Buy rating(s)	2.98
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

72.2% of Amazon.com shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 8.9% of Amazon.com shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Amazon.com had 226 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 277 mentions for Amazon.com and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Amazon.com's score of 0.94 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amazon.com	179 Very Positive mention(s)	45 Positive mention(s)	26 Neutral mention(s)	21 Negative mention(s)	4 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	44 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a net margin of 35.00% compared to Amazon.com's net margin of 17.44%. Vertex Pharmaceuticals' return on equity of 23.09% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amazon.com	17.44%	18.00%	8.97%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Amazon.com is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amazon.com	$716.92B	3.93	$77.67B	$12.43	21.00
Vertex Pharmaceuticals	$12.00B	11.57	$3.95B	$17.18	31.86

Summary

Amazon.com and Vertex Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Axsome Therapeutics presently has a consensus target price of $267.60, suggesting a potential upside of 25.10%. Vertex Pharmaceuticals has a consensus target price of $563.50, suggesting a potential upside of 2.96%. Given Axsome Therapeutics' higher probable upside, research analysts clearly believe Axsome Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

Vertex Pharmaceuticals has a net margin of 35.00% compared to Axsome Therapeutics' net margin of -24.68%. Vertex Pharmaceuticals' return on equity of 23.09% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.55	-$183.17M	-$3.75	N/A
Vertex Pharmaceuticals	$12.00B	11.57	$3.95B	$17.18	31.86

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

In the previous week, Vertex Pharmaceuticals had 41 more articles in the media than Axsome Therapeutics. MarketBeat recorded 51 mentions for Vertex Pharmaceuticals and 10 mentions for Axsome Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Axsome Therapeutics' score of 1.17 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	44 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Vertex Pharmaceuticals had 48 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 51 mentions for Vertex Pharmaceuticals and 3 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat CRISPR Therapeutics' score of 0.66 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	44 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,627.01	-$581.60M	-$4.76	N/A
Vertex Pharmaceuticals	$12.00B	11.57	$3.95B	$17.18	31.86

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 35.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. Vertex Pharmaceuticals' return on equity of 23.09% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

CRISPR Therapeutics currently has a consensus target price of $68.06, suggesting a potential upside of 15.23%. Vertex Pharmaceuticals has a consensus target price of $563.50, suggesting a potential upside of 2.96%. Given CRISPR Therapeutics' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Alphabet (NASDAQ:GOOG) and Vertex Pharmaceuticals (NASDAQ:VRTX) are related large-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Alphabet currently has a consensus target price of $415.55, suggesting a potential upside of 22.79%. Vertex Pharmaceuticals has a consensus target price of $563.50, suggesting a potential upside of 2.96%. Given Alphabet's stronger consensus rating and higher possible upside, analysts clearly believe Alphabet is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphabet	0 Sell rating(s)	4 Hold rating(s)	30 Buy rating(s)	6 Strong Buy rating(s)	3.05
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92

27.3% of Alphabet shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 13.0% of Alphabet shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Alphabet had 157 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 208 mentions for Alphabet and 51 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Alphabet's score of 0.76 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphabet	112 Very Positive mention(s)	35 Positive mention(s)	40 Neutral mention(s)	17 Negative mention(s)	3 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	44 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Alphabet has a net margin of 54.77% compared to Vertex Pharmaceuticals' net margin of 35.00%. Alphabet's return on equity of 51.32% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphabet	54.77%	51.32%	35.42%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Alphabet has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphabet	$402.84B	10.27	$132.17B	$19.91	17.00
Vertex Pharmaceuticals	$12.00B	11.57	$3.95B	$17.18	31.86

Summary

Alphabet beats Vertex Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Vertex Pharmaceuticals has higher revenue and earnings than Intuitive Surgical. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	11.57	$3.95B	$17.18	31.86
Intuitive Surgical	$10.06B	13.74	$2.86B	$8.73	44.83

Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vertex Pharmaceuticals has a net margin of 35.00% compared to Intuitive Surgical's net margin of 28.45%. Vertex Pharmaceuticals' return on equity of 23.09% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.00%	23.09%	16.72%
Intuitive Surgical	28.45%	16.91%	14.83%

Vertex Pharmaceuticals presently has a consensus target price of $563.50, indicating a potential upside of 2.96%. Intuitive Surgical has a consensus target price of $508.68, indicating a potential upside of 29.96%. Given Intuitive Surgical's higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.92
Intuitive Surgical	1 Sell rating(s)	8 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.68

In the previous week, Vertex Pharmaceuticals had 30 more articles in the media than Intuitive Surgical. MarketBeat recorded 51 mentions for Vertex Pharmaceuticals and 21 mentions for Intuitive Surgical. Vertex Pharmaceuticals' average media sentiment score of 1.48 beat Intuitive Surgical's score of 0.72 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	44 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Intuitive Surgical	11 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Intuitive Surgical on 11 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$138.72B	$4.00B	$7.29B	$12.79B
Dividend Yield	N/A	3.66%	2.55%	10.29%
P/E Ratio	31.82	11.83	269.25	24.15
Price / Sales	11.57	1,339.42	615.11	98.81
Price / Cash	30.05	102.56	78.23	52.73
Price / Book	6.86	17.16	13.24	6.23
Net Income	$3.95B	-$12.52M	$3.47B	$347.82M
7 Day Performance	5.97%	3.41%	1.85%	-0.33%
1 Month Performance	13.90%	6.76%	4.99%	2.46%
1 Year Performance	38.78%	61.42%	28.36%	20.51%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	4.2372 of 5 stars	$547.29 -0.9%	$563.50 +3.0%	+41.3%	$138.72B	$12.00B	31.82	6,400	Positive News
AMZN Amazon.com	4.9315 of 5 stars	$261.31 -0.5%	$322.56 +23.4%	+16.6%	$2.82T	$716.92B	21.02	1,576,000	Trending News Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	3.4577 of 5 stars	$216.27 +1.2%	$267.60 +23.7%	+96.1%	$11.33B	$638.50M	N/A	380	Positive News Analyst Upgrade
CRSP CRISPR Therapeutics	2.5459 of 5 stars	$54.28 +1.4%	$68.06 +25.4%	+10.4%	$5.18B	$11M	N/A	460
GOOG Alphabet	4.8663 of 5 stars	$341.45 -0.6%	$415.55 +21.7%	+68.7%	$4.18T	$445.87B	17.15	190,200	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Which has more risk and volatility, AMZN or VRTX?

Do analysts prefer AMZN or VRTX?

Do institutionals and insiders believe in AMZN or VRTX?

Does the media prefer AMZN or VRTX?

Is AMZN or VRTX more profitable?

Which has preferable earnings & valuation, AMZN or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Do analysts recommend AXSM or VRTX?

Is AXSM or VRTX more profitable?

Which has higher valuation and earnings, AXSM or VRTX?

Do institutionals and insiders hold more shares of AXSM or VRTX?

Which has more risk & volatility, AXSM or VRTX?

Does the media favor AXSM or VRTX?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Do insiders & institutionals hold more shares of CRSP or VRTX?

Does the media favor CRSP or VRTX?

Which has stronger valuation and earnings, CRSP or VRTX?

Which has more risk & volatility, CRSP or VRTX?

Is CRSP or VRTX more profitable?

Do analysts prefer CRSP or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Do analysts rate GOOG or VRTX?

Do institutionals and insiders have more ownership in GOOG or VRTX?

Does the media prefer GOOG or VRTX?

Is GOOG or VRTX more profitable?

Which has more volatility & risk, GOOG or VRTX?

Which has better earnings and valuation, GOOG or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Which has stronger earnings and valuation, VRTX or ISRG?

Which has more risk & volatility, VRTX or ISRG?

Do institutionals & insiders have more ownership in VRTX or ISRG?

Is VRTX or ISRG more profitable?

Do analysts prefer VRTX or ISRG?

Does the media favor VRTX or ISRG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools